相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc analysis
Jonathan M. Wilson et al.
DIABETES OBESITY & METABOLISM (2022)
Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes
Melissa K. Thomas et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)
The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials
Thinzar Min et al.
DIABETES THERAPY (2021)
Obesity and GLP-1
Alejandra Perez-Montes De Oca et al.
MINERVA ENDOCRINOLOGY (2021)
GIP analogues and the treatment of obesity-diabetes
Clifford J. Bailey
PEPTIDES (2020)
GIP as a Potential Therapeutic Target for Atherosclerotic Cardiovascular Disease-A Systematic Review
Yusaku Mori et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Recent advances of GIP and future horizons
Jens Juul Holst et al.
PEPTIDES (2020)
An overview of GLP-1 agonists and recent cardiovascular outcomes trials
Kelsey H. Sheahan et al.
POSTGRADUATE MEDICAL JOURNAL (2020)
Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes
Mark L. Hartman et al.
DIABETES CARE (2020)
Drug Therapy in Obesity: A Review of Current and Emerging Treatments
David M. Williams et al.
DIABETES THERAPY (2020)
The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selectivelong-acting GLP-1 receptor agonists
Shweta Urva et al.
DIABETES OBESITY & METABOLISM (2020)
Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of theLEADERandSUSTAIN6 trials
Subodh Verma et al.
DIABETES OBESITY & METABOLISM (2020)
A Role for GLP-1 in Treating Hyperphagia and Obesity
Harvey J. Grill
ENDOCRINOLOGY (2020)
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Francis S. Willard et al.
JCI INSIGHT (2020)
How May GIP Enhance the Therapeutic Efficacy of GLP-1?
Ricardo J. Samms et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2020)
GLP-1 receptor agonists in the treatment of type 2 diabetes-state-of-the-art
Michael A. Nauck et al.
MOLECULAR METABOLISM (2020)
Evaluation and management of residual cardiovascular risk in patients with diabetes
Jose Antonio Gimeno Orna et al.
ENDOCRINOLOGIA DIABETES Y NUTRICION (2020)
The incretin system in healthy humans: The role of GIP and GLP-1
Jens Juul Hoist
METABOLISM-CLINICAL AND EXPERIMENTAL (2019)
Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake
Alice E. Adriaenssens et al.
CELL METABOLISM (2019)
The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion-A Review
David S. Mathiesen et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
GLP-1 receptor agonists and cardiovascular outcome trials: An update
Eirini Andrikou et al.
HELLENIC JOURNAL OF CARDIOLOGY (2019)
Twincretin as a potential therapeutic for the management of type 2 diabetes with obesity
Ryota Usui et al.
JOURNAL OF DIABETES INVESTIGATION (2019)
Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism
Piotr A. Mroz et al.
MOLECULAR METABOLISM (2019)
Inactivation of the Glucose-Dependent Insulinotropic Polypeptide Receptor Improves Outcomes following Experimental Myocardial Infarction
John R. Ussher et al.
CELL METABOLISM (2018)
Nitric oxide signalling in cardiovascular health and disease
Charlotte Farah et al.
NATURE REVIEWS CARDIOLOGY (2018)
A novel GLP-1/xenin hybrid peptide improves glucose homeostasis, circulating lipids and restores GIP sensitivity in high fat fed mice
Annie Hasib et al.
PEPTIDES (2018)
The incretin hormone GIP is upregulated in patients with atherosclerosis and stabilizes plaques in ApoE-/- mice by blocking monocyte/macrophage activation
Florian Kahles et al.
MOLECULAR METABOLISM (2018)
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
Tamer Coskun et al.
MOLECULAR METABOLISM (2018)
Glucose-Dependent Insulinotropic Polypeptide Suppresses Peripheral Arterial Remodeling in Male Mice
Yusaku Mori et al.
ENDOCRINOLOGY (2018)
Gastric inhibitory polypeptide receptor antagonist, SKL-14959, suppressed body weight gain on diet-induced obesity mice
T. Nakamura et al.
OBESITY SCIENCE & PRACTICE (2018)
A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents
Pia K. Norregaard et al.
DIABETES OBESITY & METABOLISM (2018)
Glucagon, a key factor in the pathophysiology of type 2 diabetes
Jean Girard
BIOCHIMIE (2017)
Central administration of GLP-1 and GIP decreases feeding in mice
Cherl NamKoong et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2017)
The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes
Juan Pablo Frias et al.
CELL METABOLISM (2017)
Macrophage-mediated cholesterol handling in atherosclerosis
Dimitry A. Chistiakov et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2016)
Suppressive Effects of Glucose-Dependent Insulinotropic Polypeptide on Cardiac Hypertrophy and Fibrosis in Angiotensin II-Infused Mouse Models
Munenori Hiromura et al.
CIRCULATION JOURNAL (2016)
Anti-inflammatory role of glucose-dependent insulinotropic polypeptide in periodontitis
Yuki Suzuki et al.
JOURNAL OF DIABETES INVESTIGATION (2016)
The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions
Michael A. Nauck et al.
LANCET DIABETES & ENDOCRINOLOGY (2016)
Increased GIP signaling induces adipose inflammation via a HIF-1α-dependent pathway and impairs insulin sensitivity in mice
Shu Chen et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2015)
Macrophage subsets in atherosclerosis
Giulia Chinetti-Gbaguidi et al.
NATURE REVIEWS CARDIOLOGY (2015)
Molecular Imaging of Vascular Inflammation
Nobuhiro Tahara et al.
CURRENT PHARMACEUTICAL DESIGN (2014)
Chronic Reduction of GIP Secretion Alleviates Obesity and Insulin Resistance Under High-Fat Diet Conditions
Daniela Nasteska et al.
DIABETES (2014)
Long-Acting Glucose-Dependent Insulinotropic Polypeptide Ameliorates Obesity-Induced Adipose Tissue Inflammation
Chen Varol et al.
JOURNAL OF IMMUNOLOGY (2014)
Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action
Jonathan E. Campbell et al.
CELL METABOLISM (2013)
Role of Glucose-Dependent Insulinotropic Polypeptide in Adipose Tissue Inflammation of Dipeptidylpeptidase 4-Deficient Rats
Shani Ben-Shlomo et al.
OBESITY (2013)
Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Brian Finan et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas
Yutaka Seino et al.
JOURNAL OF DIABETES INVESTIGATION (2013)
Glucose-Dependent Insulinotropic Polypeptide Prevents the Progression of Macrophage-Driven Atherosclerosis in Diabetic Apolipoprotein E-Null Mice
Yukinori Nogi et al.
PLOS ONE (2012)
GIP-Overexpressing Mice Demonstrate Reduced Diet-Induced Obesity and Steatosis, and Improved Glucose Homeostasis
Su-Jin Kim et al.
PLOS ONE (2012)
Glucagon-like peptide-1 receptor dimerization differentially regulates agonist signaling but does not affect small molecule allostery
Kaleeckal G. Harikumar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice
M. Nagashima et al.
DIABETOLOGIA (2011)
Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
Sreenivasa Rao Kondapally Seshasai et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Sub-chronic administration of stable GIP analog in mice decreases serum LPL activity and body weight
Ewa Szalowska et al.
PEPTIDES (2011)
GIP and GLP-1, the two incretin hormones: Similarities and differences
Yutaka Seino et al.
JOURNAL OF DIABETES INVESTIGATION (2010)
Exogenous Glucose-Dependent Insulinotropic Polypeptide Worsens Postprandial Hyperglycemia in Type 2 Diabetes
Chee W. Chia et al.
DIABETES (2009)
Functional expression of glucose-dependent insulinotropic polypeptide receptors is coupled to differentiation in a human adipocyte model
R. E. Weaver et al.
INTERNATIONAL JOURNAL OF OBESITY (2008)
Physiology of GIP - A lesson from GIP receptor knockout mice
Y Yamada et al.
HORMONE AND METABOLIC RESEARCH (2004)
The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide - Regardless of etiology and phenotype
T Vilsboll et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients
T Vilsboll et al.
DIABETOLOGIA (2002)
Glucose-dependent insulinotropic peptide signaling pathways in endothelial cells
Q Zhong et al.
PEPTIDES (2000)
分享论文
